Wang Jiesheng, Dai Guanhai, Li Weijia
Department of Cadre Health, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China.
Basic Laboratory, Institute of Traditional Chinese Medicine of Zhejiang Province, Hangzhou 310007, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016 May 25;45(5):486-492. doi: 10.3785/j.issn.1008-9292.2016.09.06.
To investigate the effect of berberine on glycemia regulation in rats with diabetes and the related mechanisms. Diabetic-like rat model was successfully induced by intraperitoneal injection of streptozotocin in 50 out of 60 male SD rats, which were then randomly divided into 5 groups with 10 rats in each:control group (received vehicle only), positive drug control group (sitagliptin 10 mg·kg·d), low-dose berberine group (30 mg·kg·d), moderate-dose berberine group (60 mg·kg·d), and high-dose berberine group (120 mg·kg·d). All animals were fed for 3 d, and fasting blood sampling was performed on day 3 of administration. Rats were given glucose (2 g/kg) by gavage 30 min after the last dose. Blood and intestinal samples were obtained 2 h after glucose loading. Fasting blood glucose (FBG) and 2-h postprandial plasma glucose (2h-PPG) were detected by using biochemical analyzer, and insulin, glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-Ⅳ(DPP-Ⅳ) were measured by using ELISA kit. No significant difference in FBG and serum DPP-Ⅳ level were found between berberine groups and control group (all >0.05). Compared with control group, serum levels of GLP-1 and insulin were increased in high-and moderate-dose berberine groups, while 2h-PPG was decreased (all <0.05); GLP-1 levels in the intestinal samples were increased, while DPP-Ⅳ levels were decreased in all berberine groups (all <0.05). Short-term berberine administration can decrease 2h-PPG level in streptozotocin-induced diabetic rat model through local inhibition of intestinal DPP-Ⅳ. The efficacy of DPP-Ⅳ inhibitor may be associated with its intestinal pharmacokinetics.
研究黄连素对糖尿病大鼠血糖调节的作用及其相关机制。60只雄性SD大鼠中,50只通过腹腔注射链脲佐菌素成功诱导出糖尿病样大鼠模型,然后将其随机分为5组,每组10只:对照组(仅接受赋形剂)、阳性药物对照组(西他列汀10 mg·kg·d)、低剂量黄连素组(30 mg·kg·d)、中剂量黄连素组(60 mg·kg·d)和高剂量黄连素组(120 mg·kg·d)。所有动物喂养3天,并在给药第3天进行空腹采血。在最后一剂给药30分钟后,通过灌胃给予大鼠葡萄糖(2 g/kg)。葡萄糖负荷后2小时采集血液和肠道样本。使用生化分析仪检测空腹血糖(FBG)和餐后2小时血糖(2h-PPG),并使用ELISA试剂盒测定胰岛素、胰高血糖素样肽-1(GLP-1)和二肽基肽酶-Ⅳ(DPP-Ⅳ)。黄连素组和对照组之间的FBG和血清DPP-Ⅳ水平无显著差异(均>0.05)。与对照组相比,高剂量和中剂量黄连素组的血清GLP-1和胰岛素水平升高,而2h-PPG降低(均<0.05);所有黄连素组肠道样本中的GLP-1水平升高,而DPP-Ⅳ水平降低(均<0.05)。短期给予黄连素可通过局部抑制肠道DPP-Ⅳ降低链脲佐菌素诱导的糖尿病大鼠模型中的2h-PPG水平。DPP-Ⅳ抑制剂的疗效可能与其肠道药代动力学有关。